千亿轮回：康方生物、科伦博泰、药明合联

会会药咖11-24

编者按：本文来自UmabsDB：作者丨UmabsDB；会会药咖授权转载，编辑会会药咖今年以来，虽然创新药启动了一轮荡气回肠的火热行情，但过去三个月以来，备受资金关注的创新药板块进入持续调整通道，相关龙头企业市值反复震荡。今日随着最新一轮回调，康方生物盘中跌去4.77%，市值重回千亿港币以下，这是继科伦博泰和药明合联后，近期再一轮回千亿的企业。此前2025年7月4日，康方生物在阿斯利康潜在引进...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2585543022?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-24 08:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2585543022","market":"hk","top_or_hot":-1,"title":"千亿轮回：康方生物、科伦博泰、药明合联","media":"会会药咖","content":"<div>\n<p>编者按：本文来自UmabsDB：作者丨UmabsDB；会会药咖授权转载，编辑会会药咖今年以来，虽然创新药启动了一轮荡气回肠的火热行情，但过去三个月以来，备受资金关注的创新药板块进入持续调整通道，相关龙头企业市值反复震荡。今日随着最新一轮回调，康方生物盘中跌去4.77%，市值重回千亿港币以下，这是继科伦博泰和药明合联后，近期再一轮回千亿的企业。此前2025年7月4日，康方生物在阿斯利康潜在引进...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124081103a70cf2c2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>千亿轮回：康方生物、科伦博泰、药明合联</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n千亿轮回：康方生物、科伦博泰、药明合联\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-24 08:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124081103a70cf2c2&s=b><strong>会会药咖</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>编者按：本文来自UmabsDB：作者丨UmabsDB；会会药咖授权转载，编辑会会药咖今年以来，虽然创新药启动了一轮荡气回肠的火热行情，但过去三个月以来，备受资金关注的创新药板块进入持续调整通道，相关龙头企业市值反复震荡。今日随着最新一轮回调，康方生物盘中跌去4.77%，市值重回千亿港币以下，这是继科伦博泰和药明合联后，近期再一轮回千亿的企业。此前2025年7月4日，康方生物在阿斯利康潜在引进...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124081103a70cf2c2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0540923850.HKD","symbol_name":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124081103a70cf2c2&s=b","article_id":"2585543022","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124081103a70cf2c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2585543022","pubTimestamp":1763942439,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"今日随着最新一轮回调，康方生物盘中跌去4.77%，市值重回千亿港币以下，这是继科伦博泰和药明合联后，近期再一轮回千亿的企业。2025年8月5日，科伦博泰首次冲上千亿市值宝座，一度在10月3日达到1354亿港币市值，上市两年多以来，股价上涨超过8倍。康方生物、科伦博泰、药明合联市值跌破千亿，不仅是市场情绪的冷却，更是行业从“估值驱动”向“业绩驱动”转型的标志。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1141":"生命科学工具和服务","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","BK1161":"生物科技","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK1574":"生物医药B类股","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","02268":"药明合联","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","09926":"康方生物","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","SG9999014674.SGD":"Nikko AM All China Equity A SGD"},"translate_title":"Hundreds of billions of reincarnations: Kangfang Bio, Kelun Botai, WuXi United","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1.5,"09926":1.5},"content_text":"编者按：本文来自UmabsDB：作者丨UmabsDB；会会药咖授权转载，编辑会会药咖今年以来，虽然创新药启动了一轮荡气回肠的火热行情，但过去三个月以来，备受资金关注的创新药板块进入持续调整通道，相关龙头企业市值反复震荡。今日随着最新一轮回调，康方生物盘中跌去4.77%，市值重回千亿港币以下，这是继科伦博泰和药明合联后，近期再一轮回千亿的企业。此前2025年7月4日，康方生物在阿斯利康潜在引进Summit的PD-1/VEGF双抗的利好消息推动下，首次冲上千亿市值宝座，一度在8月27日达到1648亿港币市值。2025年8月5日，科伦博泰首次冲上千亿市值宝座，一度在10月3日达到1354亿港币市值，上市两年多以来，股价上涨超过8倍。2025年10月2日，作为全球XDC偶联药物的CRDMO领导者，药明合联市值首次突破千亿港币，达到1030亿港币，自2023年11月上市以来上涨了超3倍。三者作为当前生物医药医药领域，肿瘤免疫双抗、ADC药物和复杂偶联药物CRDMO的典型代表，其市值在千亿附近反复跳拨，或将进一步坚实创新药的确定性。一方面意味着估值理性回归，泡沫逐步出清。此前，创新药板块因政策利好、出海预期、技术突破等催化，估值快速拉升，部分公司市值一度脱离基本面。如今市值回落，意味着市场正从“概念炒作”转向“业绩验证”，估值逐步回归合理区间，有利于行业长期健康发展。同时也加速商业化的进一步落地，当前部分创新药企业中期业绩不及预期，核心产品收入下降引发市场担忧，投资者开始更关注企业盈利能力和商业化进展，而非仅靠管线故事支撑估值。此外尽管国家医保局持续释放支持创新药的政策信号（如“新药首发价格机制”、医保目录调整等），但市场对政策落地效果持观望态度，短期内难以抵消业绩和估值双重压力。尽管短期承压，但创新药行业的长期逻辑依然稳固，市值回落可能为中长期投资者提供更好的布局窗口。康方生物、科伦博泰、药明合联市值跌破千亿，不仅是市场情绪的冷却，更是行业从“估值驱动”向“业绩驱动”转型的标志。短期调整虽剧烈，但也为真正具备商业化能力和国际化潜力的企业提供了价值重估的机会。千亿市值的反复轮回是继续坚定中国创新药发展的必然之路，希望反复调拨后，将迎来更坚实的发展。往期阅读推荐（点击标题跳转到对应原文）1.《全球首创！益科思特CD3CD19双抗在美国启动膜性肾病临床》2.《PD-1/VEGF双抗的“一盆冷水”》3.《葛兰素史克5000万美元重磅押注中国生物科技》4.《强生的500亿美元计划》5.《PD-(L)1/VEGF双抗三步走，肿瘤竞赛上了新高度》6.《MNC强势砸钱入场》7.《谁是国内小核酸领域“黑马”？》8.《全球疫苗大失速》9.《20.45亿！来凯医药重磅产品授权齐鲁制药》10.《礼来又创新高！》11.《黑石的创新药赌局》12.《诺和诺德裁员9000人，细胞疗法部门全部关门》13.《宇宙大药厂，气不过》14.《全球“药王”易主，替尔泊肽“上位”》“Related information is being updated”《最先破防的，是诺和诺德》《再鼎怎么了？》《Biotech一哥，扔出新王炸》《CGT重磅：FDA官宣上市新通道》《全球前二，收获大单》《眼科CGT起风了》《强生要做“一哥”》《创新药回不去了》《哪家MNC最钟爱中国资产？》《千亿黄金赛道再出新BD》《迈威生物的确定性与想象性》《CAR-T的“生死谈判”》","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585543022","isCrawlerRequest":true}